Tags

Type your tag names separated by a space and hit enter

[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Orv Hetil 2000; 141(31):1711-4OH

Abstract

The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients. The diagnosis was stated endoscopically. Hp infection was confirmed from 2 antral + 2 corporeal biopsies by the modified Giemsa stain and rapid urease test. After eradication the patients were given on-demand treatment with 30 mg lansoprazole (group I) or 2 x 150 mg ranitidine (group II). Control 13C-urea breath test was performed 4-6 weeks after eradication. On intention to treat basis, Hp was eradicated in 78.3% (confidence interval, CI: 67.6-89.1%) in group I and 78.7% (CI: 68.1-89.2%) in group II (p > 0.05). Per protocol eradication rates were 92.1% (CI: 84.5-99.7%) in group I and 90.5 (CI: 82.4-98.6%) in group II (p > 0.05). Side effects were recorded in 13.5% in group I and 18.3% of cases in group II. Short term triple therapies using either lansoprazole or ranitidine bismuth citrate + 2 antimicrobials were effective and safe in the eradication of Hp in duodenal ulcer patients.

Authors+Show Affiliations

Gasztroenterológia, Ferencvárosi Egészségügyi Szolgálat, Budapest.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
English Abstract
Journal Article

Language

hun

PubMed ID

10976194

Citation

Buzás György, M, et al. "[Lansoprazole Versus Ranitidine Bismuth Citrate Containing Triple Regimens for Helicobacter Pylori Eradication in Patients With Duodenal Ulcer]." Orvosi Hetilap, vol. 141, no. 31, 2000, pp. 1711-4.
Buzás György M, Székely E, Illyés G, et al. [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. Orv Hetil. 2000;141(31):1711-4.
Buzás György, M., Székely, E., Illyés, G., & Széles, I. (2000). [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. Orvosi Hetilap, 141(31), pp. 1711-4.
Buzás György M, et al. [Lansoprazole Versus Ranitidine Bismuth Citrate Containing Triple Regimens for Helicobacter Pylori Eradication in Patients With Duodenal Ulcer]. Orv Hetil. 2000 Jul 30;141(31):1711-4. PubMed PMID: 10976194.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. AU - Buzás György,M, AU - Székely,E, AU - Illyés,G, AU - Széles,I, PY - 2000/9/8/pubmed PY - 2000/10/7/medline PY - 2000/9/8/entrez SP - 1711 EP - 4 JF - Orvosi hetilap JO - Orv Hetil VL - 141 IS - 31 N2 - The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients. The diagnosis was stated endoscopically. Hp infection was confirmed from 2 antral + 2 corporeal biopsies by the modified Giemsa stain and rapid urease test. After eradication the patients were given on-demand treatment with 30 mg lansoprazole (group I) or 2 x 150 mg ranitidine (group II). Control 13C-urea breath test was performed 4-6 weeks after eradication. On intention to treat basis, Hp was eradicated in 78.3% (confidence interval, CI: 67.6-89.1%) in group I and 78.7% (CI: 68.1-89.2%) in group II (p > 0.05). Per protocol eradication rates were 92.1% (CI: 84.5-99.7%) in group I and 90.5 (CI: 82.4-98.6%) in group II (p > 0.05). Side effects were recorded in 13.5% in group I and 18.3% of cases in group II. Short term triple therapies using either lansoprazole or ranitidine bismuth citrate + 2 antimicrobials were effective and safe in the eradication of Hp in duodenal ulcer patients. SN - 0030-6002 UR - https://www.unboundmedicine.com/medline/citation/10976194/[Lansoprazole_versus_ranitidine_bismuth_citrate_containing_triple_regimens_for_Helicobacter_pylori_eradication_in_patients_with_duodenal_ulcer]_ L2 - https://medlineplus.gov/helicobacterpyloriinfections.html DB - PRIME DP - Unbound Medicine ER -